Novartis presents important overall survival and quality-of-life results across solid.
The Pharma Data
AUGUST 30, 2021
New Kisqali ® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2? Key abstracts accepted by ESMO include: Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2?)
Let's personalize your content